First Trust Amex Biotech Index Fund (FBT): Price and Financial Metrics ETF
FBT Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market
| Current price | $166.16 | 52-week high | $179.67 |
| Prev. close | $164.94 | 52-week low | $137.97 |
| Day low | $164.00 | Volume | 10,835 |
| Day high | $166.24 | Avg. volume | 27,316 |
| 50-day MA | $171.04 | Dividend yield | N/A |
| 200-day MA | $159.32 |
FBT Stock Price Chart Interactive Chart >
First Trust Amex Biotech Index Fund (FBT) ETF Bio
The investment objective of the First Trust Amex Biotech Index Fund ETF seeks to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
FBT ETF Info
| Issuer | First Trust Portfolios |
| Expense Ratio | 0.55% |
| Underlying Index | NYSE Arca Biotechnology Index |
| Asset Class | Equity |
| Sector | Health & Biotech ETFs |
| Assets Under Management (AUM) | 1.13B |
| Net Asset Value (NAV) | $165.21 |
| Options? | Yes |
| Total Holdings | 32 |
FBT Top Holdings
| Symbol | Company | % of Total |
| EXEL | Exelixis Inc. | 4.67% |
| NTRA | Natera Inc. | 4.18% |
| INCY | Incyte Corporation | 4.13% |
| CORT | Corcept Therapeutics Incorporated | 4.11% |
| ACAD | ACADIA Pharmaceuticals Inc. | 4.05% |
| ITCI | Intra-Cellular Therapies Inc. | 3.86% |
| ARGX | argenx SE (ADR) | 3.75% |
| GILD | Gilead Sciences Inc. | 3.69% |
| CPRX | Catalyst Pharmaceuticals Inc. | 3.66% |
| NBIX | Neurocrine Biosciences Inc. | 3.61% |
FBT Price Returns
| 1-mo | -2.83% |
| 3-mo | -2.49% |
| 6-mo | 9.68% |
| 1-year | 18.40% |
| 3-year | 6.43% |
| 5-year | 18.74% |
| YTD | 5.13% |
| 2023 | 2.55% |
| 2022 | -4.83% |
| 2021 | -2.26% |
| 2020 | 12.96% |
| 2019 | 19.74% |